GB1153927A - Medicinal Composition Suitable For Treating Diseases Of The Retina - Google Patents
Medicinal Composition Suitable For Treating Diseases Of The RetinaInfo
- Publication number
- GB1153927A GB1153927A GB38700/67A GB3870067A GB1153927A GB 1153927 A GB1153927 A GB 1153927A GB 38700/67 A GB38700/67 A GB 38700/67A GB 3870067 A GB3870067 A GB 3870067A GB 1153927 A GB1153927 A GB 1153927A
- Authority
- GB
- United Kingdom
- Prior art keywords
- agents
- pharmacologically acceptable
- retina
- cations
- aug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000001525 retina Anatomy 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- -1 dimethyl fumaric acid compound Chemical class 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- MFGALGYVFGDXIX-UHFFFAOYSA-N 2,3-Dimethylmaleic anhydride Chemical compound CC1=C(C)C(=O)OC1=O MFGALGYVFGDXIX-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 239000003957 anion exchange resin Substances 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 150000004982 aromatic amines Chemical class 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 229920001429 chelating resin Polymers 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 abstract 1
- CGBYBGVMDAPUIH-ARJAWSKDSA-N dimethylmaleic acid Chemical compound OC(=O)C(/C)=C(/C)C(O)=O CGBYBGVMDAPUIH-ARJAWSKDSA-N 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 229910001411 inorganic cation Inorganic materials 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229940099273 magnesium trisilicate Drugs 0.000 abstract 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 abstract 1
- 235000019793 magnesium trisilicate Nutrition 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 150000002892 organic cations Chemical class 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 229920001568 phenolic resin Polymers 0.000 abstract 1
- 239000005011 phenolic resin Substances 0.000 abstract 1
- 150000003141 primary amines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003335 secondary amines Chemical class 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
- 239000001993 wax Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1,153,927. Medicinal compositions. W. HORRMANN. 22 Aug., 1967 [25 Aug., 1966], No. 38700/67. Heading A5B. A medicinal composition for the treatment of diseases of the retina particularly macular degeneration comprises dimethylmaleic anhydride and/or a dimethylmaleic and/or dimethyl fumaric acid compound having the following general formula: wherein each of R and R 1 , which may be the same or different, represents a hydrogen atom, a pharmacologically acceptable cation or a pharmacologically acceptable group corresponding to a mono-or polyhydric alcohol from which the or one hydroxyl group has been removed; in admixture with a pharmacologically acceptable carrier or diluent therefor. Examples of suitable cations are inorganic cations such as Na, Ca and ammonium ions and organic cations such as are produced by anion exchange resins of the primary, secondary and tertiary amine type e.g. Amberlite (Trade Mark), styrene and phenolic resins and polycondensates of an aromatic and/or aliphatic amine with an aldehyde or ketone. The alcohol may be be ethanol, glycol, glycerol, 1,2-propylene glycol, mannitol or sorbitol. The compositions may be administered orally, parenterally or topically and may be in the form of tablets, diffusion pellets, suppositories, syrups, aqueous solutions or capsules containing binding agents, expanding agents, delaying action agents (e.g. lipoids, fats, waxes and salts of fatty acids), tasteimproving agents (e.g. sugar and lactose), antacids (such as magnesium oxide, hydrated magnesium trisilicate and aluminium hydroxide), natural and synthetic gums and mucouslike materials (such as methylcellulose, carboxycellulose and dextrans).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57490366A | 1966-08-25 | 1966-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1153927A true GB1153927A (en) | 1969-06-04 |
Family
ID=24298124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB38700/67A Expired GB1153927A (en) | 1966-08-25 | 1967-08-22 | Medicinal Composition Suitable For Treating Diseases Of The Retina |
Country Status (3)
Country | Link |
---|---|
DE (1) | DE1617528B1 (en) |
FR (1) | FR6666M (en) |
GB (1) | GB1153927A (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
EP1799196A2 (en) | 2004-10-08 | 2007-06-27 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2014031894A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
EP2811994A1 (en) | 2012-02-07 | 2014-12-17 | Biogen Idec MA Inc. | Pharmaceutical compositions containing dimethyl fumarate |
US8980832B2 (en) | 2003-09-09 | 2015-03-17 | Biogen Idec International Gmbh | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
US9452972B2 (en) | 2008-08-19 | 2016-09-27 | Xenoport, Inc. | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
EP3302461A4 (en) * | 2015-06-01 | 2019-02-13 | Sun Pharmaceutical Industries Ltd | Pharmaceutical compositions of dimethyl fumarate |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
-
1967
- 1967-08-22 GB GB38700/67A patent/GB1153927A/en not_active Expired
- 1967-08-23 DE DE1967H0063687 patent/DE1617528B1/en not_active Withdrawn
- 1967-08-24 FR FR118820A patent/FR6666M/fr not_active Expired
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980832B2 (en) | 2003-09-09 | 2015-03-17 | Biogen Idec International Gmbh | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
EP2965751A1 (en) | 2004-10-08 | 2016-01-13 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP3470064A1 (en) | 2004-10-08 | 2019-04-17 | Fwp Ip Aps | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP2316430A1 (en) | 2004-10-08 | 2011-05-04 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP3459532A1 (en) | 2004-10-08 | 2019-03-27 | Fwp Ip Aps | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
DE202005022112U1 (en) | 2004-10-08 | 2014-04-24 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US11052062B2 (en) | 2004-10-08 | 2021-07-06 | Biogen Swiss Manufacturing Gmbh | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP2792349A2 (en) | 2004-10-08 | 2014-10-22 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP2801354A1 (en) | 2004-10-08 | 2014-11-12 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP2801355A1 (en) | 2004-10-08 | 2014-11-12 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US11229619B2 (en) | 2004-10-08 | 2022-01-25 | Biogen Swiss Manufacturing Gmbh | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP3093012A1 (en) | 2004-10-08 | 2016-11-16 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
EP1799196A2 (en) | 2004-10-08 | 2007-06-27 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2007042035A3 (en) * | 2005-10-07 | 2007-06-14 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
US9452972B2 (en) | 2008-08-19 | 2016-09-27 | Xenoport, Inc. | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof |
US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
US11173123B2 (en) | 2009-01-09 | 2021-11-16 | Biogen Swiss Manufacturing Gmbh | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
EP2782561A1 (en) | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
EP2811994A1 (en) | 2012-02-07 | 2014-12-17 | Biogen Idec MA Inc. | Pharmaceutical compositions containing dimethyl fumarate |
WO2014031894A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US10940117B2 (en) | 2012-08-22 | 2021-03-09 | Arbor Pharmaceuticals, Llc | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
US10716760B2 (en) | 2012-08-22 | 2020-07-21 | Arbor Pharmaceuticals, Llc | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
US11938111B2 (en) | 2013-03-24 | 2024-03-26 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
US9682057B2 (en) | 2013-09-06 | 2017-06-20 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
WO2015042294A1 (en) | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
US11135296B2 (en) | 2014-03-24 | 2021-10-05 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of fumaric acid esters |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
EP3302461A4 (en) * | 2015-06-01 | 2019-02-13 | Sun Pharmaceutical Industries Ltd | Pharmaceutical compositions of dimethyl fumarate |
Also Published As
Publication number | Publication date |
---|---|
DE1617528B1 (en) | 1970-12-10 |
FR6666M (en) | 1969-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1153927A (en) | Medicinal Composition Suitable For Treating Diseases Of The Retina | |
GB1159449A (en) | New Piperidinoalkanol Derivatives | |
DE2534391A1 (en) | 1-HYDROXY-3-AMINOALKANE-1,1-DIPHOSPHONIC ACIDS | |
ES355462A1 (en) | Lubricant compositions | |
GB1084009A (en) | Derivatives of 1,2,3,4-tetrahydro-9-aminoacridine | |
DE2343197A1 (en) | PHARMACEUTICAL OR COSMETIC PREPARATIONS | |
US4077997A (en) | Diphosphonoalkane carboxylic acids, process of preparation and methods of use | |
GB1264775A (en) | ||
GB1199065A (en) | Theophylline and Theobromine Compounds and processes for their production | |
GB1285372A (en) | Improvements in or relating to prostaglandins and the preparation thereof | |
FR2197577A1 (en) | Hypocholesterolaemic, antiatheroma agents - 3,5-diiodo-4-(3-iodo-4-alkoxy-carbonyl phenoxy) phenylalkanoic acids, esters and salts | |
NO145272B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF A PHARMACOLOGICAL ACTIVE MIXED SALT OF A SULPHOGLYCLOPOPTIME AND NITROGEN CONTAINING ORGANIC BASE | |
GB1065716A (en) | Tetracycline derivatives and process for their preparation | |
US1703732A (en) | Complex antimony compounds and process of making same | |
GB1425560A (en) | 1-substituted-4-benzamido-piperidines and methods for their preparation | |
DE870560C (en) | Process for preparing nitrogen-disubstituted ªª, ª-diphenylethylamines | |
GB1062299A (en) | 3,4-dihydroxyphenyl-propane derivatives | |
Campbell et al. | The preparation of amino alcohols | |
GB925890A (en) | Drug/resin adsorbates and a process for the manufacture of same | |
GB1037658A (en) | Phenylethanolamine derivatives | |
GB529382A (en) | Manufacture of derivatives of aliphatic amino-sulphonic acids | |
GB1311004A (en) | Dibenzocycloheptenes | |
GB1288892A (en) | ||
GB1272416A (en) | Tetracycline derivatives and a process for the preparation thereof | |
WO2023097322A3 (en) | Skin care composition |